India’s contribution a mere 2% in clinical research – BioSpectrum Asia
0
Despite being home to one sixth of the world’s population and carrying one fifth of the world’s disease burden, yet less than 2 percent of global clinical research takes place in India. This is bad news for patients suffering from critical diseases. The reasons for the decrease include issues such as regulatory hassles, anti-trial activists, compensation issues, patient deaths etc.
Ms Suneela Thatte, president, Indian Society for Clinical Research (ISCR) said,
“The quest for finding superior and lifesaving medicines is an ongoing one. For every medicine and device that gets a marketing approval, there is a larger story of years of research in laboratories and extensive patient participation in clinical trials to determine their safety and efficacy.”
She further added,
“Patients help patients. Today all of us have access to better and newer treatments because of patients who have participated in clinical trials. Thus, we are all beneficiaries of clinical research. Yet it is unfortunate that the progress of clinical research in India has been stalled by several extraneous factors denying patients the opportunity to participate in and benefit from ongoing clinical research. The impact of this on patients is huge. A slowdown in clinical research in the country means little or no access to newer and better medicines for our patients and a rising disease burden.”
“Due to the existing tumultuous clinical trials milieu in the country, new drug development is totally hampered. We have a huge rise in the number of NCDs including depression, hypertension, and cancer, and soon we will be the diabetes capital of the world. At the same time, there are diseases which are reflective of a developing economy like TB, malaria, and leprosy among others. Unfortunately, we do not have satisfactory treatments for these diseases. Also, we have HIV, and recently the Ebola, for which there is no cure at present,” emphasized Ms Thatte.
“If we do not forge into clinical research and drug development, soon we will face issues for which we will not have satisfactory access to medicines,” she added.
Read more – BioSpectrum Asia